Find thousands of books, manuscripts, visual materials and unpublished archives from our collections, many of them with free online access.

20 Rapid HIV-1/2 Antibody tests and sample developer solutio

Science Museum, London
  • Digital Images
  • Online

Available online

view 20 Rapid HIV-1/2 Antibody tests and sample developer solutio


Attribution 4.0 International (CC BY 4.0)
You can use this work for any purpose, including commercial uses, without restriction under copyright law. You should also provide attribution to the original work, source and licence.
Creative Commons Attribution (CC BY 4.0) terms and conditions
Credit: 20 Rapid HIV-1/2 Antibody tests and sample developer solutio. Credit: Science Museum, London. Attribution 4.0 International (CC BY 4.0)

Selected images from this work

About this work


The OraQuick Advance Rapid HIV-1/2 Antibody tests are used for clinical HIV testing of blood and saliva samples. The OraQuick tests are in development and under FDA (United States Food and Drug Administration) trials as a self-administered HIV test. They are for patients to carry out under the supervision of a trained person and are for use in outreach programmes and mobile clinics. It is pain-free and requires neither a blood sample or laboratory testing. The patient sweeps between the gum and teeth with a swab, which is placed in the stand for 20-40 minutes. The swab then indicates a positive or negative result. Twenty antibody tests are shown with a sample developer solution vial and plastic stand. The kit was made by Orasure Technologies. HIV (Human Immunodeficiency Virus) is the virus that develops into AIDS. It can be transmitted via bodily fluids during unprotected sex, blood transfusions or sharing hypodermic needles. Symptoms may not appear for many years so it is possible to unknowingly infect other people during this time. The manufacturer claims that of those infected with HIV in the US, nearly a quarter are unaware of their condition. maker: Orasure Technologies Place made: United States


Permanent link

We’re improving the information on this page. Find out more.